Name the medicine first

A broad name leaves too much open

When someone mentions peptide treatment, ask for the actual medicine name. Keep the ingredient beside any brand name and note the form being discussed. If a service uses its own label for a plan, ask what medicine sits inside that plan. The plan name is not enough to check against an original source or discuss with another professional.

Peptide names a kind of substance. As of September 2026, that name did not tell you whether a product had drug approval or met the rules for compounding. Semaglutide, including the brands Ozempic and Wegovy, had FDA-approved products in the September 2026 record. The name Food and Drug Administration is commonly shortened to FDA. The category matters, but so does the precise product and use being discussed.

Check what the product record says

In September 2026, the tirzepatide medicines Mounjaro and Zepbound also held FDA approvals. The approved uses differ between products, so an approval for an ingredient does not make every brand interchangeable for every condition. Ask the professional to identify the product they mean and the use they are considering.

You can ask to see the current product information and have unfamiliar terms put into everyday words. Keep the question focused: what is this product, what is the proposed use, and what does that mean for my concern? There is no need to memorize a group of drug names before the conversation.

Compounding is a separate description

For a compounded preparation, a pharmacist, doctor, or registered facility makes the drug rather than dispensing a finished medicine from a drug company. In September 2026, compounded preparations had no FDA approval. Before sale, FDA did not review their safety, quality, or whether they worked. Ask what need in your case led the prescriber to propose compounding.

Do not let a shared ingredient name do all the work in a comparison. Ask which pharmacy makes the preparation, what the proposed difference is, and how the prescriber arrived at that choice. Keep the answer with the product name. The compounding chapter separates that question from advertising about customization.

A research label answers a different question

In its 2026 enforcement letters, FDA treated some products bearing research-use labels as unapproved drugs because the websites promoted human use. Those letters set out allegations against particular firms, not court judgments. A label describing research does not give you the assessment, prescribing decision, or follow-up conversation you came looking for.

Ask the person proposing a medicine to describe its status directly. A long technical name or an entry in a government's searchable records can be hard to interpret without context. As of September 2026, FDA expressly said an NDC listing was not evidence of drug approval. NDC means National Drug Code, a product identifier used in a directory.

Write down what remains unknown

If an ingredient or product name is unclear, ask for it again in writing. If the explanation shifts from a medicine to a broad promise about wellness, return to the exact proposal. You can leave space for an unanswered question without agreeing to the plan. A clear record makes the next conversation more useful.

Bring that record to the assessment or to another professional you already see. Ask them to distinguish the product's status from whether it fits your circumstances. Then read what compounding changes, or move to reading a health claim if you are trying to judge an offer or article.